2026-02-26 - TMO - Thermo Fisher Scientific Deep Dive

Article published Feb 26, 2026. Prices below use latest available snapshots.

TMO Price Structure

Loading chart…

Loading timeframes…

Conviction: Medium-High Status: Watching — RSI 32.2 approaching neutral, price recovering +0.3% today, SMA gap tightening

Quick Snapshot

Signal	Reading
Overall	🟡 RSI 32.2 — recovered from extreme 5.5 on 02/16 and 19.2 on 02/22. Price $515.03, +0.3% today, +2.7% this week. -17.8% in 30 days. SMA declining toward price.
Moat	Wide (lab equipment, reagents, instruments monopoly)
Key insight	TMO continues its RSI recovery — from extreme 5.5 → 19.2 → 32.2. Price is showing steady improvement (+2.7% this week). SMA20 ($535.17) declining fast. The life sciences picks-and-shovels thesis is unchanged. Insider selling ($323.3M) remains the key risk. RSI approaching the oversold/neutral boundary — next reading above 35 would signal a clear technical recovery.

Action Matrix

Action	Level	Why
Current	✅ Buy	RSI 32.2 — recovering from extreme. Wide moat. Price recovering with RSI.
Entry Zone	$490 - $525	Current $515.03 — IN ZONE
Stop-Loss	$440 (-15%)	Below multi-year support
Target	$650 (+26%)	Recovery toward SMA and prior levels

Extended analysis

Price Data

Stock	Price	1D	7D	30D	3M	52wkHi	RSI	Status	Action
TMO	$515.03	+0.3%	+2.7%	-17.8%	—	-17.8%	32	🟡 Approaching Neutral	✅ Buy

Price vs Last Deep Dive (02/22)

Metric	02/22	02/26	Change
Price	$510.93	$515.03	+$4.10 (+0.8%)
RSI	19.2	32.2	+13.0 (continued recovery)
SMA20	$556.36	$535.17	-$21.19 (SMA declining fast)
vs SMA	-8.2%	-3.8%	Gap narrowing rapidly

Update from 02/22: TMO's RSI recovery continues — from extreme 5.5 (02/16) to 19.2 (02/22) to 32.2 now. Price has also improved modestly from $510.93 to $515.03 (+0.8%). This week's +2.7% is encouraging. The SMA20 has dropped sharply from $556 to $535, and the price gap has narrowed from -8.2% to -3.8%. TMO is in a clear technical recovery pattern: RSI recovering in steps, SMA declining to meet price, gap narrowing. At RSI 32.2, it's approaching the oversold/neutral boundary. The Buy action is maintained — still in the entry zone.

Company Overview

One-Liner

Thermo Fisher Scientific is the world's largest life sciences company, providing analytical instruments, equipment, reagents, and services to every lab and pharma company globally.

Business Model

Question	Answer
What they sell	Lab instruments/equipment, scientific reagents, specialty chemicals, CRO/bioprocessing services
Who pays	Pharma/biotech (50%), hospitals/diagnostic labs (20%), academic/government (20%), industrial (10%)
Revenue model	Equipment sales (one-time), consumables/reagents (recurring), service contracts, bioproduction (recurring)
How sticky	Very high — scientific instruments require calibration, reagents are qualified per protocol, switching risks experiment reproducibility

Key Segments

Segment	Revenue %	Growth	Notes
Life Sciences Solutions	~35%	+8% YoY	Reagents, bioprocessing, gene editing tools
Analytical Instruments	~25%	+6% YoY	Mass spec, chromatography, electron microscopy
Specialty Diagnostics	~20%	+5% YoY	Clinical diagnostic kits, allergy testing
Laboratory Products & Biopharma Services	~20%	+4% YoY	Lab supplies, CRO services (PPD)

Competitive Analysis

Competitive Moat

Moat Type	Present?	Evidence
Switching costs	🟢	Scientific protocols lock in specific instruments/reagents; revalidation cost is prohibitive
Intangible assets	🟢	Thermo, Fisher Scientific, Life Technologies brand trust in research community
Network effects	🟡	Scientific literature references specific TMO instruments/reagents
Cost advantages	🟢	$45B+ revenue generates unmatched supply chain scale
Efficient scale	🟢	Only company covering full lab workflow from sample prep to analysis

Moat Width: Wide Moat Trend: Stable — life sciences R&D spend is structural, not cyclical long-term

TMO vs IQV (Comparison)

Both are life sciences compounders — but diverging in recovery:

Metric	TMO	IQV
RSI	32.2	17.4
30D	-17.8%	-32.2%
Moat	Wide	Wide
Revenue	$45B	$16B
Insider Selling	$323.3M	-$39.8M
Recovery Signal	RSI +13 pts this week	RSI deteriorating

Bull Case

Why This Could Work

Essential life sciences infrastructure — Every hospital, pharma company, and lab needs TMO products. No substitution.
Bioproduction secular tailwind — mRNA, cell therapy, gene editing all require TMO's bioprocessing equipment.
RSI recovery 5.5 → 19.2 → 32.2 — Steady, sustained recovery pattern — most constructive in our coverage.
Picks-and-shovels for pharma AI — AI drug discovery increases demand for analytical instruments.
SMA gap narrowing from -8.2% → -3.8% — Convergence accelerating.

Upside Scenario

If This Happens	Stock Could
Bioproduction recovery + multiple normalization	$650 (+26%)
Pharma R&D spending re-acceleration	$700 (+36%)

Bear Case

What Could Go Wrong

Pharma R&D budget cuts — Largest customer segment cutting spending post-COVID boom.
Insider selling $323.3M — Among highest in our universe alongside ISRG.
China exposure — ~15% China revenue; geopolitical risk on analytical instruments.
CRO competition — PPD segment (acquired 2021) faces IQVIA competition.

Thesis Killers

Pharma top 10 companies announce R&D budget cuts exceeding 10%
China bans TMO instrument imports
Bioproduction demand collapses (mRNA era over)

Entry Strategy

Technical Levels

Level	Price	Notes
Support 1	$490	Recent floor / entry zone bottom
Support 2	$440	Stop-loss; multi-year support
Resistance 1	$535.17	SMA20 — declining toward price
Resistance 2	$580	3-month prior range
52-week high	$626.62	In-window high
52-week low	~$460	(estimated)

Entry Approach

Strategy	Details
Entry zone	$490 - $525
Starter	2% of portfolio
Add	RSI breaks above 35 with price above $520
Full	RSI > 40 + SMA20 convergence

Research Log

Date	Update
2026-02-16	Created deep dive. RSI 5.5 extreme (!). $504.82. -13% below SMA. Insider selling $323.3M. Action: Buy.
2026-02-22	Price refresh. $510.93 (+1.2%). RSI 19.2 (from 5.5 — largest improvement in coverage: +13.7 pts). SMA gap narrowed from -13% to -8.2%. Still extreme oversold. Buy maintained.
2026-02-26	Price continued recovery to $515.03 (+0.8%). RSI 19.2 → 32.2 (+13 pts — steady recovery). SMA gap narrowed from -8.2% → -3.8%. 7D +2.7%. Approaching oversold/neutral boundary. Buy maintained — near entry zone top.

The Gold

Key Discoveries

Discovery	Implication
RSI 5.5 → 19.2 → 32.2 = steady stepwise recovery	Most constructive recovery pattern in coverage; not a false bounce
SMA gap: -13% → -8.2% → -3.8% in 10 days	SMA converging — price may reach SMA without a big price move
Price: $504 → $510 → $515 — steady upward	Price recovering alongside RSI — both signals aligned
7D +2.7% vs IQV 7D -8.4%	TMO diverging positively from CRO peer IQV

Open Questions

What drove the RSI 5.5 extreme — was it forced selling/index rebalancing?
Are the insider sales ($323.3M) on scheduled 10b5-1 plans?
What is TMO's China revenue exposure and risk?
When does TMO report next earnings?
Why is TMO recovering while IQV continues to deteriorate? (Both life sciences, different dynamics)

Mistakes (Don't Repeat)

Mistake	Lesson
None yet	Stepwise RSI recovery (5.5 → 19 → 32) is the cleanest buy signal pattern we track

Sources

Fundamentals figures: company-reported results (quarterly/annual filings) as available at the artifact date; predates the desk's EDGAR reconciliation gate — figures not re-verified after publication.